Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$505.16 USD

505.16
2,142,054

-6.10 (-1.19%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $505.17 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (190 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT

by Zacks Equity Research

Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

ELV vs. AVTR: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. AVTR: Which Stock Is the Better Value Option?

Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.

BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.

Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.

HCA Healthcare's (HCA) Q4 Earnings Beat on Improved Admissions

by Zacks Equity Research

HCA Healthcare (HCA) expects EPS in the range of $19.70-$21.20 for 2024, the midpoint being 7.6% higher than the 2023 figure.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked

by Zacks Equity Research

Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.

Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 1.26% and 1.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Elevance Health (ELV) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Elevance Health (ELV) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.

ELV or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. HQY: Which Stock Is the Better Value Option?

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Why You Should Retain Elevance (ELV) Stock in Your Portfolio

by Zacks Equity Research

Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.

Why Elevance Health (ELV) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Elevance Health (ELV) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Elevance Health (ELV) stood at $475.12, denoting a -1.49% change from the preceding trading day.

Here's Why Elevance Health (ELV) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Elevance Health (ELV) & Verizon Partner to Bring Health Equity

by Zacks Equity Research

Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.

Elevance Health (ELV) Enhances Whole Health With Paragon Buyout

by Zacks Equity Research

Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.

Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?

by Zacks Equity Research

Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.